HEALTH CARE DECISIONS USING OUTCOMES RESEARCH CASE STUDIES
CASE1 |
UTILIZING AN INTERNET-BASED SYSTEM TO DELIVER A PHARMACY-CENTRIC ALERT AND INTERVENTION IN A MANAGED CARE SETTING |
|
Fazio J, Orr G, Singal R |
|
WorldDoc, Las Vegas, NV, USA |
| |
|
CASE2 |
ISSUES WHEN COMPARING COSTS AND EFFECTS OF INHALED ASTHMA AND COPD MEDICATIONS |
|
Engstrom A1, Hugosson K2 |
|
1LFN Pharmaceutical Benefits Board, Solna, Sweden; 2 Pharmaceutical Benefits Board, Solna, Sweden |
| |
|
CASE3 |
REVIEWING THE REIMBURSEMENT STATUS OF DRUGS AGAINST ASTHMA, COPD AND COUGHS |
|
Hugosson H1, Engstrom A2 |
|
1Pharmaceutical Benefits Board, Solna, Sweden; 2 LFN Pharmaceutical Benefits Board, Solna, Sweden |
| |
|
CASE4 |
DEVELOPMENT AND VALIDATION OF A CAREGIVER GASTROENTERORITIS KNOWLEDGE QUESTIONAIRE |
|
Deiratany S |
|
The Hospital for Sick Children, Toronto, ON, Canada |
|
|
CANCER
PCN1 |
QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) OF FOTEMUSTINE COMPARED WITH DACARBAZINE IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA |
|
Simons WR1, Aamdal S2, Hauschild A3, Mohr P4, Grob JJ5 |
|
1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2Cancer Clinic, Oslo, Norway, 3Universitats-Hautklinik, Kiel, Germany, 4Dermatologisches Zentrum, Buxtehude, Germany, 5Chu Hospitalier Sainte-Marguerite, Marseille, France |
| |
|
PCN2 |
RETROSPECTIVE CHART REVIEW OF THE MANAGEMENT OF HAND-FOOT SYNDROME IN THE TREATMENT OF COLORECTAL CANCER |
|
Ralston SJ1, Almond J1, Holtz D2 |
|
1Merck Serono, Feltham, Middlesex, UK, 2Merck Serono, West Drayton, Middlesex, UK |
| |
|
PCN3 |
ECONOMIC IMPACT OF SECOND- AND THIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER: A FRENCH OBSERVATIONAL STUDY. |
|
Chouaid C1, Vergnenegre A2, Moser A3, Coudray-Omnes C3 |
|
1CHU Saint Antoine, APHP, Paris, France, 2CHU Limoges, Limoges, France, 3Roche Pharma, Neuilly sur Seine cedex, France |
| |
|
PCN4 |
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF USING HEXAMINOLEVULINATE (HEXVIX) CYSTOSCOPY COMPARED TO WHITE LIGHT CYSTOSCOPY IN BLADDER CANCER PATIENTS |
|
Colombo GL1, Di Matteo S1, Vinci M1, Caruggi M2 |
|
1S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy, 2Università degli Studi dell'Insubria, Varese, Italy |
| |
|
PCN5 |
THE IMPORTANCE OF A RATIONAL USE OF HIGH COSTING CHEMOTHERAPY AGENTS IN A CHEMOTHERAPY UNIT OF A TERTIARY CANCER HOSPITAL IN BRAZIL |
|
Souza FH, Viana LS, Nunes JS, Schroeter D, Serrano SV |
|
Hospital de Cancer de Barretos, Barretos, SP, Brazil |
| |
|
PCN6 |
HOSPITALIZATION COSTS FOR TWO METHODS OF TSH STIMULATION DURING THE RADIOIODINE ABLATION IN THYROID CANCER PATIENTS |
|
Borget I1, Schlumberger M1, Ricard M2, Remy H2, Allyn M3, De Pouvourville G4 |
|
1Gustave Roussy Institute, Villejuif, France, 2Institut de cancérologie Gustave Roussy, Villejuif, France, 3genzyme corporation, Cambridge, MA, USA, 4ESSEC Business School, Cergy-pontoise, France |
| |
|
PCN7 |
PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN SPAIN |
|
Lopez A1, Arocho R2, Atchison C3, Malin JL4, Liu Z5, Doan QV5, Dubois RW5 |
|
1Vall d’Hebron University Hospital, Barcelona, Spain, 2Amgen SA, Barcelona, Spain, 3Amgen (Europe) Gmbh, Zug, Switzerland, 4Amgen Inc, Thousand Oaks, CA, USA, 5Cerner Corporation, Beverly Hills, CA, USA |
| |
|
PCN8 |
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA): THE ITALIAN CASE |
|
Esposito G1, Lamotte M1, Annemans L2, Bracco A3 |
|
1IMS Health, Brussels, Belgium, 2Ghent University, Gent, Belgium, 3Amgen (Europe) GmbH, Zug, Switzerland |
| |
|
PCN9 |
COST-EFFECTIVENESS OF SUPERFICIAL BLADDER CANCER SURVEILLANCE IN WHICH CYSTOSCOPY IS PARTLY REPLACED BY MICROSATELLITE ANALYSIS |
|
De Bekker-Grob EW1, Van der Aa MNM2, Zwarthoff EC1, Meerding WJ1, Eijkemans MJC1, Van Rhijn BWG1, Van der Kwast TH3, Steyerberg EW1 |
|
1Erasmus MC, Rotterdam, The Netherlands, 2LUMC, Leiden, The Netherlands, 3Mount Sinai Hospital, Toronto, ON, Canada |
| |
|
PCN10 |
COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN |
|
Hsia TC1, Chang GC2, Chen YM3, Lin MC4, Su WC5, Tsai CM3, Tsai CM6, Yang L7, Creeden J8 |
|
1China Medical University Hospital, Taichung, Taiwan, 2Taichung Veterans General Hospital, Taichung, Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Chang Guang Memorial Hospital, Kaohsiung Branch, Kaohsiung, Taiwan, 5National Cheng Kung University Hospital, Tainan, Taiwan, 6Roche Taiwan, Taipei, Taiwan, 7Roche Products Ltd, Taipei, Taiwan, 8F Hoffmann La Roche, Basel, Switzerland |
| |
|
PCN11 |
COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA |
|
Logman JFS1, Taylor MJ2, Neumann K3, Kutikova L4, Cerri KH5, Van Hout BA1, Kühr T6 |
|
1Pharmerit Europe, Rotterdam, The Netherlands, 2University of York, York, UK, 3Vienna School of Evidence Based Medicine, Vienna, Austria, 4Bristol-Myers Squibb Central Europe, Prague, Czech Republic, 5Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, 6Klinikum Kreuzschwestern, Wels, Austria |
| |
|
PCN12 |
COST-EFFECTIVENESS OF TARGETED ONCOLOGY THERAPIES: A SYSTEMATIC LITERATURE REVIEW |
|
Kalpas E, Doyle J |
|
Analytica International, New York, NY, USA |
| |
|
PCN13 |
ASSESSMENT OF THE COST-EFFECTIVENESS IN AUSTRALIA OF CETUXIMAB IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CANCERS OF THE HEAD AND NECK |
|
De Abreu Lourenco R1, Houltram J1, Pearce G2 |
|
1Covance, North Ryde, New South Wales, Australia, 2Alphapharm Pty Limited, Glebe, New South Wales, Australia |
| |
|
PCN14 |
COST-EFFECTIVENESS OF EXEMESTANE VS. TAMOXIFEN IN POST-MENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN GERMANY |
|
Braun S1, Mittendorf T1, Greiner W2, Dopatka J3, von der Schulenburg JM1 |
|
1Leibniz University of Hannover, Hannover, Germany, 2University of Bielefeld, Bielefeld, Germany, 3Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
PCN15 |
ESTIMATING THE COST EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN IRELAND USING A MATHEMATICAL MODEL |
|
Redmond S1, Demarteau N2 |
|
1GlaxoSmithKline, Dublin 16, Ireland, 2IMS HEOR, Brussels, Belgium |
| |
|
PCN16 |
COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN |
|
Chao TY1, Chen SC2, Chang KJ3, Chang HK4, Chen DR5, Hou MF6, Hsieh RK7, Huang WT8, Tseng LM9, Wang HC10, Yang L11, Cirrincione A12 |
|
1Tri-Service General Hospital, Taipei, Taiwan, 2Chang Guang Memorial Hospital, Taipei Branch, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan, 4Chang Guang Memorial Hospital, Linkou Branch, Linkou, Taiwan, 5Changhua Christian Hospital, Changhua, Taiwan, 6Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 7Mackay Memorial Hospital, Taipei, Taiwan, 8Chimei Medical Center, Tainan, Taiwan, 9Taipei Veterans General Hospital, Taipei, Taiwan, 10China Medical University Hospital, Taichung, Taiwan, 11Roche Products Ltd, Taipei, Taiwan, 12F.Hoffmann-La Roche Ltd, Basel, Switzerland |
| |
|
PCN17 |
COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN PATIENTS WITH EARLY HER-2 POSITIVE BREAST CANCER IN BRAZIL |
|
Correa M1, Perdicaris M2, Vernaglia PRW3, Da Cunha FM4, Saggia MG5, Santos EA5, Nasciben V5 |
|
1Hospital do Cancer A. C. Camargo, Sao Paulo, SP, Brazil, 2Hospital Beneficência Portuguesa, Santos, SP, Brazil, 3Brazilian Institute for Cancer Control - IBCC, Sao Paulo, SP, Brazil, 4Centro médico de Campinas, Campinas, SP, Brazil, 5Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN18 |
SUNITINIB VS. INTERFERON-ALPHA (IFN-Α) IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA (MRCC): AN ECONOMIC EVALUATION |
|
Remák E1, Brown R2, Negrier S3, Motzer RJ4, Kim ST5, Charbonneau C6 |
|
1United Biosource Corporation, Budapest, Hungary, 2United BioSource Corporation, London, London, UK, 3Centre Leron Berard, Lyon, France, 4Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5Pfizer Inc, San Diego, CA, USA, 6Pfizer Inc, New York, NY, USA |
| |
|
PCN19 |
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA (QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA): THE GERMAN CASE |
|
Van Bellinghen LA1, Esposito G2, Lamotte M2, Bracco A3, Goertz A4, Annemans L5 |
|
1IMS HEOR, Brussels, Belgium, 2IMS Health, Brussels, Belgium, 3Amgen (Europe) GmbH, Zug, Switzerland, 4Amgen Germany GmbH, Munich, Germany, 5Ghent University, Gent, Belgium |
| |
|
PCN20 |
COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN THE UK |
|
Brown B1, Tilden D1, Griebsch I2, Ralston SJ3 |
|
1IMS Health, London, UK, 2Merck KGaA, Darmstadt, Germany, 3Merck Serono, Feltham, Middlesex, UK |
| |
|
PCN21 |
A HEALTH ECONOMIC EVALUATION OF HEXVIX AS ADJUNCT TO STANDARD WHITE LIGHT CYSTOSCOPY IN THE MANAGEMENT OF SUPERFICIAL BLADDER CANCER |
|
Demarteau N1, Braeckman J2, Michielsen D2, Sweet A3, Zyczynski T4, Lamotte M5 |
|
1IMS HEOR, Brussels, Belgium, 2AZ-VUB, Brussels, Belgium, 3GE Healthcare, Buckinghamshire, UK, 4GE Healthcare, Princeton, NJ, USA, 5IMS Health, Brussel, Brabant, Belgium |
| |
|
PCN22 |
COST-EFFECTIVENESS OF SUNITINIB AS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CANCER IN BELGIUM |
|
Van Nooten F1, Dewilde S1, Van Belle S2, Marbaix S3 |
|
1United BioSource Corporation, Brussels, Belgium, 2University Hospital Ghent, Gent, Belgium, 3Pfizer, Brussels, Belgium |
| |
|
PCN23 |
PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN ITALY |
|
Chiroli S1, Ciceri DF2, Atchison C3, Malin JL4, Liu Z5, Doan QV5, Dubois RW5 |
|
1Amgen, Milan, Italy, 2Istituto Scientifico San Raffaele, Milano, Italy, 3Amgen (Europe) Gmbh, Zug, Switzerland, 4Amgen Inc, Thousand Oaks, CA, USA, 5Cerner Corporation, Beverly Hills, CA, USA |
| |
|
PCN24 |
COST-EFFECTIVENESS ANALYSIS OF 5HT3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING |
|
Ruiz MA1, Garrido J1, García Pulgar M2, Alvarez Sanz C2 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Roche Farma, Madrid, Spain |
| |
|
PCN25 |
PHARMACOECONOMIC EVALUATION OF CAPECITABINE (XELODA) FOR GASTRIC CANCER IN THE UK |
|
Cowell W, Summerhayes M |
|
Roche Products Ltd, Welwyn Garden City, UK |
| |
|
PCN26 |
INNOVATION OVER THE PRODUCT LIFE CYCLE: ESTIMATING THE POTENTIAL ECONOMIC VALUE OF TRASTUZUMAB IN BREAST CANCER IN FIVE EUROPEAN COUNTRIES BETWEEN 2000 AND 2020 |
|
Garrison LP, Veenstra DL |
|
University of Washington, Seattle, WA, USA |
| |
|
PCN27 |
COST-EFFECTIVENESS OF HUMAN INTERFERON-ALPHA AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED CUTANEOUS MALIGNANT MELANOMA IN STAGE IIB & III |
|
Kasteng F1, Stadler R2, Wagenius G3, Lundkvist J1 |
|
1i3 Innovus, Stockholm, Sweden, 2Academic Medical Centre, Minden, Germany, 3Uppsala University Hospital, Uppsala, Sweden |
| |
|
PCN28 |
ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2–3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER: A FINNISH PERSPECTIVE |
|
Färkkilä N1, Kotomäki T2, Jormanainen V2 |
|
1Karolinska Institutet, Stockholm, Sweden, 2Pfizer Oy, Helsinki, Finland |
| |
|
PCN29 |
COST-EFFECTIVENESS OF MAINTENANCE RITUXIMAB TREATMENT AFTER SECOND LINE THERAPY IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPHOMA IN SWEDEN |
|
Kasteng F1, Erlanson M2, Hagberg H3, Kimby E4, Relander T5, Lundkvist J1 |
|
1i3 Innovus, Stockholm, Sweden, 2Umeå University Hospital, Umeå, Sweden, 3Uppsala University Hospital, Uppsala, Sweden, 4Karolinska University Hospital, Stockholm, Sweden, 5Lund University Hospital, Lund, Sweden |
| |
|
PCN30 |
THE ECONOMIC BENEFITS OF TEGAFUR WITH URACIL (UFTORAL) IN FIRST- LINE METASTATIC COLORECTAL CANCER |
|
Ralston SJ, Almond J |
|
Merck Serono, Feltham, Middlesex, UK |
| |
|
PCN31 |
COST MINIMIZATION ANALYSIS OF CAPECITABINE+CISPLATIN IV VS 5-FLUORURACIL IV+CISPLATIN IV AS FIRST LINE THERAPY FOR ADVANCED GASTRIC CANCER FROM THE BRAZILIAN SOCIETAL PERSPECTIVE |
|
Malzyner A1, Saggia MG2, Nasciben V2 |
|
1Hospital Brigadeiro da Secretaria da Saúde do Estado de São Paulo, Sao Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN32 |
COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL |
|
Stefani S1, Saggia MG2, Santos EA2 |
|
1UNIMED and Instituto do Câncer Mãe de Deus, Porto Alegre, RS, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN33 |
COST-MINIMIZATION ANALYSIS OF ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM VERSUS DAILY FILGRASTIM FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN BRAZIL |
|
Lago S1, Nasciben V2, Saggia MG2 |
|
1PUC-RS, Sao Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN34 |
COST MINIMIZATION ANALYSIS OF INTRA-VENOUS BIPHOSPHONATES THERAPIES AVAILABLE IN BRAZIL FOR THE PROPHYLAXIS OF SKELETAL EVENTS (SE) IN BREAST CANCER PATIENTS WITH BONE METASTASIS |
|
Perdicaris M1, Nasciben V2, Saggia MG2 |
|
1Hospital Beneficência Portuguesa, Santos, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN35 |
ASSESSING THE IMPACT ON STAFF RESOURCES AND PATIENT WAITING TIME OF A SWITCH FROM IV TO ORAL CHEMOTHERAPY WITH VINORELBINE |
|
Colombo GL1, Caruggi M2, Ottolini C3, Cortinovis D4 |
|
1S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Milano, Italy, 2Università dell'Insubria, Varese, Italy, 3Azienda Ospedaliera di Busto Arsizio, Varese, Busto Arsizio, Varese, Italy, 4Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy |
| |
|
PCN36 |
ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXED AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON–SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS |
|
Capri S1, Morabito A2, Carillio G3, Grossi F4, Longo R5, Cerea G6, Rossetti F7 |
|
1Cattaneo-LIUC University, Castellanza, (Varese), Italy, 2Istituto Nazionale Tumori, Napoli, NA, Italy, 3Humanitas Centro Catanese di Oncologia, Catania, CA, Italy, 4Istituto Nazionale per la Ricerca sul Cancro, Genova, GE, Italy, 5San Filippo Neri, Roma, RM, Italy, 6Ospedale Niguarda Ca’ Granda, Milano, MI, Italy, 7ROCHE S.p.A, Monza, MZ, Italy |
| |
|
PCN37 |
RESOURCE USE AND TIME SAVINGS IN SPAIN LINKED WITH NEW CHEMOTHERAPY PRESENTATIONS: THE CASE OF OXALIPLATIN |
|
Betegon L1, Echevarria A2, Soler F3, Quer N3 |
|
1IMS HEOR, Madrid, Spain, 2sanofi-aventis, Madrid, Spain, 3Institut Català d’Oncologia Girona, Girona, Spain |
| |
|
PCN38 |
COST-ANALYSIS OF XELOX VS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING |
|
Garrison L1, Giuliani G2, Ducournau P3, Cirrincione A3 |
|
1University of Washington, Seattle, WA, USA, 2Roche S.p.A. Italy, Monza, Italy, 3F. Hoffmann-La Roche, Basel, Switzerland |
| |
|
PCN39 |
THE COST OF TREATING AND MANAGING ABNORMAL CERVICAL CONDITIONS IN IRELAND |
|
Rash B1, Prendiville W2, Byrne P3, Stratton J4, Redmond S5 |
|
1Health Market International, Ann Arbor, MI, USA, 2Coombe Women's Hospital, Dublin, Ireland, 3Beaumont Hospital, Dublin, Ireland, 4Waterford Regional Hospital, Waterford, Ireland, 5GlaxoSmithKline, Dublin 16, Ireland |
| |
|
PCN40 |
HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT: AN ECONOMIC MODEL OF THE IMPACT ON GERMAN HEALTH CARE COSTS |
|
Sievert KD1, Zyczynski T2, Sweet A3, Rößler DW4, Stenzl A5 |
|
1Universitätsklinikum Tübingen, Tübingen, Germany, 2GE Healthcare, Princeton, NJ, USA, 3GE Healthcare, Buckinghamshire, UK, 4Caritas-Krankenhaus St. Josef, Regensburg, Germany, 5University of Tuebingen, Tübingen, Germany |
| |
|
PCN41 |
HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT: AN ECONOMIC MODEL OF THE IMPACT ON HEALTHCARE COSTS IN THE UK |
|
Zyczynski T1, Sweet A2, Wallace DM3 |
|
1GE Healthcare, Princeton, NJ, USA, 2GE Healthcare, Buckinghamshire, UK, 3Queen Elizabeth Medical Centre, Birmingham, UK |
| |
|
PCN42 |
COST ANALYSIS OF SEPSIS MANAGEMENT AFTER MYELOSUPPRESSIV CHEMOTHERAPY IN NSCLC AND LYMPHPOMA PATIENTS: A GERMAN HOSPITAL PERSPECTIVE |
|
Paessens B1, Berger K2, Ihbe-Heffinger A1, Mueller-Thomas C1, Shlaen M3, Von Schilling C4, Bernard R1, Peschel C1, Schramm W2 |
|
1Klinikum rechts der Isar der Technischen Universität München, München, Germany, 2University Hospital of Munich, München, Germany, 3Medical Economic Research Group (MERG), München, Germany, 4Klinikum Freising, Freising, Germany |
| |
|
PCN43 |
COST OF INTRAVENOUS ADMINISTRATION OF BISPHOSPHONATES IN PATIENTS WITH METASTATIC BREAST CANCER |
|
Lundkvist J1, Kasteng F1, Lindman H2, Wilking N3 |
|
1i3 Innovus, Stockholm, Sweden, 2Uppsala University Hospital, Uppsala, Sweden, 3Karolinska Institute, Stockholm, Sweden |
| |
|
PCN44 |
ADJUVANT TRASTUZUMAB TREATMENT IN EARLY STAGE BREAST CANCER: COST-EFFECTIVENESS IN THE BELGIAN HEALTHCARE SETTING |
|
Van Vlaenderen I1, Canon J2, Cocquyt V3, Jerusalem G4, Machiels J5, Neven P6, Nechelput M7, Delabaye I7, Gyldmark M8, Annemans L9 |
|
1IMS Health Belgium, Brussels, Brussels, Belgium, 2Centre Hospitalier Notre Dame et Reine Fabiola, Charleroi, Belgium, 3University Hospital Gent, Gent, Belgium, 4Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgium, 5Cliniques universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium, 6University Hospital Leuven, Leuven, Belgium, 7Roche Pharmaceuticals, Brussels, Belgium, 8F. Hoffmann - La Roche, Basel, Switzerland, 9Ghent University, Gent, Belgium |
| |
|
PCN45 |
UK COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS GENERIC PACLITAXEL ONCE WEEKLY AND NAB-PACLITAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) PROGRESSED AFTER ANTHRACYCLINE CHEMOTHERAPY M |
|
Benedict Á1, Cameron D2, Corson H3, Jones S4 |
|
1United BioSource Corporation, Budapest, Hungary, 2University of Leeds, Leeds, UK, 3sanofi-aventis, Bagneux, France, 4US Oncology Research, Houston, TX, USA |
| |
|
PCN46 |
A COST UTILITY ANALYSIS OF MAINTENANCE RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR NON HODGKINS LYMPHOMA (NHL) IN THE UK |
|
Geary U1, Lewis G2, Aultman R3, Aristides M4 |
|
1Roche Products Limited, Hertfordshire, UK, 2Roche Products Limited, Welwyn Garden City, Herts, UK, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4IMS Health, London, UK |
| |
|
PCN47 |
COST-UTILITY ANALYSIS OF OXALIPLATIN IN THE ADJUVANT TREATMENT OF COLON CANCER IN HUNGARY |
|
Muszbek N1, Odhiambo R2 |
|
1UnitedBiosource Corporation, London, UK, 2sanofi-aventis Zrt, Budapest, Hungary |
| |
|
PCN48 |
SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) – AN ECONOMIC EVALUATION USING BAYESIAN APPROACH |
|
Purmonen T1, Martikainen JA1, Soini EJ2, Kataja V3, Kellokumpu-Lehtinen P4 |
|
1Centre for Pharmaceutical Policy and Economics (CEPPE), University of Kuopio, Kuopio, Finland, 2Centre for Pharmaceutical Policy and Economics (CEPPE) and Department of Health Policy and Management, University of Kuopio, Kuopio, Finland, 3Kuopio University Hospital and Vaasa Central Hospital, Kuopio, Finland, 4Tampere University Hospital and University of Tampere, Tampere, Finland |
| |
|
PCN49 |
COST-UTILITY ANALYSIS OF MAINTENANCE THERAPY WITH RITUXIMAB FOR FOLLICULAR LYMPHOMA IN BRAZIL |
|
Chiattone CS1, Saggia MG2, Santos EA2 |
|
1Faculdade de Ciências Médicas da Santa Casa de Sao Paulo, Sao Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil |
| |
|
PCN50 |
COST SHIFTING EFFECT IN DRG BASED ANTI-CANCER THERAPIES IN HUNGARY |
|
Jozsa G |
|
University of West Hungary, Sopron, Hungary |
| |
|
PCN51 |
WITHDRAWN |
|
|
|
|
| |
|
PCN52 |
GAP BETWEEN TREATMENT COST OF AND MORTALITY DUE TO CERVICAL CANCER IN HUNGARY |
|
Boncz I1, Péntek M2, Ágoston I1, Betlehem J1, Karpati K3, Brodszky V3, Gulácsi L3, Sebestyén A4 |
|
1University of Pécs, Pécs, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3Corvinus University of Budapest, Budapest, Hungary, 4National Health Insurance Fund Administration, Pécs, Hungary |
| |
|
PCN53 |
EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN OVER 64 YEARS |
|
Boncz I1, Betlehem J1, Ember I1, Sebestyén A2 |
|
1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration (OEP), Pécs, Hungary |
| |
|
PCN54 |
INCREASING EXPENDITURES FOR ONCOLOGY MEDICATIONS: CZECH REPUBLIC LONG-TERM DATA |
|
Skoupá J1, Cerna V1, Doležal T2 |
|
1Pharma Projects, Prague, Czech Republic, 23-rd Medical Faculty Charles University, Prague, Czech Republic |
| |
|
PCN55 |
THE IMPACT OF 21-GENE RT-PCR ASSAY ON REAL LIFE TREATMENT DECISIONS IN N-, ER+ EARLY-STAGE BREAST CANCER PATIENTS: IT'S IMPLICATION FOR BUDGET IMPACT ANALYSIS |
|
Hammerman A1, Klang SH2, Liebermann N2, Efrat N3 |
|
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Clalit Health Services, Tel-Aviv, Israel, 3Kaplan Medical Center, Rehovot, Israel |
| |
|
PCN56 |
INTERNATIONAL INCIDENCE OF MEN WITH UNCERTAIN INDICATION FOR RADICAL PROSTATECTOMY: AN EVIDENCE-BASED ANALYSIS |
|
Lee DW1, Dann RA2, Lintner MJ1, Zhang B3, Friedman M3, Menzin J3 |
|
1GE Healthcare, Waukesha, WI, USA, 2GE Healthcare, Chalfont St Giles, UK, 3Boston Health Economics, Waltham, MA, USA |
| |
|
PCN57 |
BASIC ATTITUDE TO USE OF GENERIC ANTI-CANCER DRUGS FOR BREAST CANCER TREATMENT IN JAPAN |
|
Saito S1, Shimozuma K2, Ohashi Y3, Fukuda T3, Fukui N4, Mouri M4, Kuroi K5 |
|
1Kochi Women's University, Kochi, Japan, 2Ritsumeikan University, Kusatsu, Shiga, Japan, 3University of Tokyo, Bunkyo-ku, Tokyo, Japan, 4Japan Clinical Research Support Unit, Bunkyo-ku, Tokyo, Japan, 5Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo, Japan |
| |
|
PCN58 |
BREAST CANCER SCREENING PROGRAMS: EVALUATION ASIDE FROM CLINICAL AND ECONOMICAL ASPECTS |
|
Radlberger P |
|
Ludwig Boltzmann Institute of Health Technology Assessment, Vienna, Austria |
| |
|
PCN59 |
TREATMENT PATTERNS FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) IN GERMANY |
|
Jenkins A1, Aristides M1, Liepa AM2, Relf C3, Feilding B3 |
|
1IMS Health Economics and Outcomes Research, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 3IMS Health, Sittingbourne, UK |
| |
|
PCN60 |
IMPLEMENTATION AND EVALUATION OF CLINICAL PATHWAYS IN AN ONCOLOGY ELECTRONIC MEDICAL RECORD |
|
Conner TM1, Beveridge R2, Lokay K3, Young D3, Johnston A3 |
|
1Outcomes Research Consulting, Austin, TX, USA, 2US Oncology, Fairfax, VA, USA, 3US Oncology, Houston, TX, USA |
| |
|
PCN61 |
MULTI-STATE SURVIVAL ANALYSIS IN COST-EFFECTIVENESS STUDIES: THE CASE OF CAPECITABINE VERSUS DOCETAXEL IN METASTATIC BREAST CANCER (MBC) FOR A PRIVATE PAYER IN BRAZIL |
|
Santos EA1, Marques RM2 |
|
1Roche Brazil, Sao Paulo, SP, Brazil, 2Hospital Sirio Libanês, São Paulo, São Paulo, Brazil |
| |
|
PCN62 |
USE OF A 5-LEVEL EQ-5D IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA |
|
Holtzer-Goor KM1, Thompson SL1, Schaafsma MR2, Uyl-de Groot C1 |
|
1institute for Medical Technology Assessment, Rotterdam, Zuid-Holland, The Netherlands, 2Medisch Spectrum Twente, Enschede, The Netherlands |
| |
|
PCN63 |
META-ANALYTIC, TRIAL-LEVEL APPROACH TO VALIDATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT IN ADVANCED BREAST CANCER |
|
Miksad R1, Zietemann V2, Mattheucci Gothe R2, Schwarzer R2, Conrads-Frank A2, Schnell-Inderst P2, Stollenwerk B2, Plieschnegger P2, Esteban E2, Siebert U2 |
|
1Beth Israel Deaconess Medical Center / Institute for Technology Assessment / Harvard University, Boston, MA, USA, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Hall, Tirol, Austria |
| |
|
PCN64 |
CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN) |
|
Mallick R1, Hudes G2, Levy DE3 |
|
1Wyeth Research, Collegeville, PA, USA, 2Fox Chase Cancer Center, Philadelphia, PA, USA, 3Wyeth Pharmaceuticals, Cambridge, MA, USA |
| |
|
PCN65 |
RESULTS FROM MABEL: QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC) |
|
Glynne - Jones R1, Esser R2, Ralston SJ3 |
|
1Mount Vernon Hospital, Northwood, Middlesex, UK, 2Merck KGaA, Darmstadt, Germany, 3Merck Serono, Feltham, Middlesex, UK |
| |
|
PCN66 |
DEFINING HEALTH STATE UTILITIES FOR HAND-FOOT-SYNDROME |
|
Roth S1, Simons S1, Güney D1, Reineking N1, Dietrich ES2, Jaehde U1 |
|
1University of Bonn, Bonn, NRW, Germany, 2TK Scientific Institute for Benefit and Efficiency in Health Care, Hamburg, Germany |
| |
|
PCN67 |
ESTIMATION OF IMPORTANT DIFFERENCES IN EQ-5D VAS SCORES IN CANCER |
|
Pickard AS1, Neary MP2, Cella D3 |
|
1College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 2GlaxoSmithKline, Collegeville, PA, USA, 3Evanston Northwestern Healthcare, Evanston, IL, USA |
| |
|
PCN68 |
SENSITIVITY TO CHANGE OF THE PERFORM QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING IMPROVEMENT OR DETERIORATION OF THEIR CANCER-RELATED FATIGUE |
|
Baro E1, Cassinello J2, Carulla J3, Valentín V4, Rodríguez C5, Gascón P6, García-Mata J7, Colomer R8, Gasquet JA9, Perform group G10 |
|
13D Health Research, Barcelona, Spain, 2Hospital Universitario de Guadalajara, Guadalajara, Spain, 3Hospital Verge del Toro, Menorca, Spain, 4Hospital 12 de octubre, Madrid, Spain, 5Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 6Hospital Clínic i Provincial de Barcelona, Barcelona, Spain, 7Hospital Santa Maria Nai, Orense, Spain, 8Centro Oncológico MD Anderson, Madrid, Spain, 9AMGEN S.A, Barcelona, Spain, 10The PERFORM Study Group, Barcelona, Spain |
| |
|
PCN69 |
PATIENT-REPORTED IMPAIRMENT OF EUROQOL HEALTH STATES AND PREFERENCE-WEIGHTED UTILITY IN ADVANCED RENAL CELL CARCINOMA IN A RECENT CLINICAL TRIAL |
|
Mallick R1, Sun S1, Hudes G2 |
|
1Wyeth Research, Collegeville, PA, USA, 2Fox Chase Cancer Center, Philadelphia, PA, USA |
| |
|
PCN70 |
UTILITY VALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKAEMIA (CML): ESTIMATES FROM LAYPERSONS IN AUSTRALIA, THE UK (UK) AND CANADA |
|
Levy AR1, Szabo SM1, Tabberer M2, Davis C3 |
|
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Oxford Outcomes Ltd, Oxford, Oxon, UK, 3Bristol-Myers Squibb, Wallingford, CT, USA |
| |
|
PCN71 |
CONJOINT ANALYSIS A TECHNIQUE TO DEVELOP A QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH LUNG CANCER |
|
Perulero N1, Cardenal F2, Garcia R3, Juan O4, Vázquez S5, Barneto I6, Varela C7 |
|
1IMS Health, Barcelona, Spain, 2ICO. Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain, 3Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4Hospital Arnau de Vilanova, Valencia, Spain, 5Complexo Hospitalario Xeral Calde, Lugo, Spain, 6Hospital General Universitario Reina Sofía, Córdoba, Spain, 7Roche Farma, Madrid, Spain |
| |
|
PCN72 |
HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND KIDNEY CANCER-RELATED SYMPTOMS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA IN A RANDOMISED, MULTINATIONAL PHASE III TRIAL: RESULTS FOR EUROPEAN AND US SUBSAMPLE ANALYSES |
|
Cella D1, Li JZ2, Bushmakin AG3, Cappelleri JC4, Kim ST2, Chen I2, Charbonneau C5, Motzer RJ6 |
|
1Evanston Northwestern Healthcare, Evanston, IL, USA, 2Pfizer Inc, San Diego, CA, USA, 3Pfizer, Inc, Groton, CT, USA, 4Pfizer Inc, Groton, CT, USA, 5Pfizer Inc, New York, NY, USA, 6Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| |
|
PCN73 |
LINGUISTIC VALIDATION OF THE HOT FLASH DIARY FOR PROSTATE CANCER PATIENTS IN EIGHT LANGUAGES FOR NINE COUNTRIES |
|
Eremenco S1, Arnold B1, Weinstein D2, Sendersky V2 |
|
1Evanston Northwestern Healthcare, Evanston, IL, USA, 2Ferring Pharmaceuticals, Copenhagen, Denmark |
| |
|
PCN74 |
PSYCHOSOCIAL CONSEQUENCES OF ABNORMAL AND FALSE-POSITIVE RESULTS IN LUNG CANCER SCREENING: ADAPTATION OF A QUESTIONNAIRE |
|
Thorsen H, Brodersen J |
|
University of Copenhagen, Copenhagen, Denmark |
| |
|
PCN75 |
WHAT CHOICES DO MEN FEEL THEY HAVE IN SELECTION OF PROSTATE CANCER TREATMENT? |
|
Ramsey SD1, Zeliadt SD1, Hall IJ2, Lee JW2, Ekwueme DU2, Moinpour CM1, Penson D3 |
|
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Centers for Disease Control and Prevention, Atlanta, GA, USA, 3University of Southern California / Norris Cancer Center, Los Angeles, CA, USA |
| |
|
PCN76 |
COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT |
|
Marshall DA1, Johnson FR2, Kulin NA1, Ozdemir S2, Marshall JK1, Walsh J3, Van Bebber S3, Phillips KA3 |
|
1McMaster University, Hamilton, ON, Canada, 2RTI International, Research Triangle Park, NC, USA, 3University of California, San Francisco, San Francisco, CA, USA |
| |
|
PCN77 |
PHARMACOECONOMIC ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NON-SMALL-CELL LUNG CANCER (NSCLC) IN TURKEY |
| |
Batigun O, Yildirim E |
|
Roche Müstahzarlari Sanayi AS, Istanbul, Maslak-Istanbul, Turkey |
EYE
PEY1 |
USE OF BAYESIAN NETWORKS TO SPECIFY NOCTURNAL IOP CONTROL BY PROSTAGLANDIN ANALOGUES ACCORDING TO SEVERAL THRESHOLDS FROM DAY-TIME MEASUREMENTS IN GLAUCOMA PATIENTS |
|
Nordmann JP1, Berdeaux G2 |
|
1Centre Hospitalier National des Quinze-Vingts, Paris, France, 2Alcon France, Rueil-Malmaison, France |
| |
|
PEY2 |
INTRA-OCULAR PRESSURE CONTROL OF XALACOM ® (FIXED LATANOPROST AND TIMOLOL COMBINATION) AND DUOTRAV ® (FIXED TRAVOPROST AND TIMOLOL COMBINATION) IN DAILY PRACTICE |
|
Lafuma A1, Jeanbat V1, Laurendeau C1, Berdeaux G2 |
|
1Cemka-Eval, Bourg-la-Reine, France, 2Alcon France, Rueil-Malmaison, France |
| |
|
PEY3 |
RANIBIZUMAB (LUCENTIS®) IS A COST-EFFECTIVE TREATMENT OF AGE-RELATED MACULA DEGENERATION (AMD) IN THE GERMAN HEALTH CARE SYSTEM |
|
Neubauer AS1, Back EI2, Kuehn T2, Thomas VS3 |
|
1Eye Hospital of the Ludwig-Maximilians-University, Munich, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany, 3Novartis Pharma AG, Basel, Switzerland |
| |
|
PEY4 |
COST-EFFECTIVENESS ANALYSIS OF FIXED COMBINATION THERAPIES GANFORT, DUOTRAV AND XALACOM IN EUROPEAN COUNTRIES |
|
Hommer AB1, Friis M2, Wickstrom J2, Poulsen PB2, Walt JG3, Buchholz P4 |
|
1Krankenhaus Hera Vienna, Vienna, Austria, 2MUUSMANN Research & Consulting A/S, Kolding, Denmark, 3Allergan Inc, Irvine, CA, USA, 4Allergan Europe, Ettlingen, Germany |
| |
|
PEY5 |
COST-EFFECTIVENESS MODELING OF LUCENTIS VERSUS USUAL CARE IN AGE RELATED MACULAR DEGENERESCENCE |
|
Beresniak A1, Cohen S2, Quentel G2, Mimoun G3, Citterio T4, Bremond-Gignac D5 |
|
1Data Mining International, Geneva, Switzerland, 2Imaging and Laser centre, Paris, France, 3Eye Medical Centre, Paris, France, 4Novartis Pharmaceuticals, Rueil-Malmaison, France, 5Robert Debre Hospital, Paris, France |
| |
|
PEY6 |
COST OF CATARACT SURGERY AFTER IMPLANTATION OF THREE INTRAOCULAR LENSES WITH SQUARE EDGES |
|
Smith AF1, Lafuma A2, Jeanbat V2, Boureau C3, Dubois V4 |
|
1Alcon Laboratories Ltd, Hemel Hempstead, Herts, UK, 2Cemka-Eval, Bourg-la-Reine, France, 3Ophthalmologist, Paris, France, 4Laboratoire Alcon, Rueil Malmaison, France |
| |
|
PEY7 |
BELGIAN COST-UTILITY ANALYSIS OF LUCENTIS (RANIBIZUMAB) IN WET AGE RELATED MACULAR DEGENERATION
|
|
Moeremans K1, Annemans L2, Lecomte P3 |
|
1IMS Health, Brussel, Belgium, 2Ghent University, Ghent, Belgium, 3Novartis Pharmaceuticals, Vilvoorde, Belgium |
| |
|
PEY8 |
A EUROPEAN SURVEY OF PATIENT SATISFACTION WITH SPECTACLES AND THE ASSOCIATED COSTS IN FIVE EUROPEAN COUNTRIES |
|
Lafuma A1, Laurendeau C1, Lamerain E2, Berdeaux G3 |
|
1Cemka-Eval, Bourg-la-Reine, France, 2TNS Sofres, Montrouge, France, 3Alcon France, Rueil-Malmaison, France |
| |
|
PEY9 |
COST OF STANDARD CARE TREATMENT IN THE UK AMONG PATIENTS WITH PROGRESSION OF PRIMARY OPEN ANGLE GLAUCOMA |
|
Walt JG1, Chiang TH1, Stern L2, Doyle J2, Berenson K2 |
|
1Allergan Inc, Irvine, CA, USA, 2Analytica International, New York, NY, USA |
| |
|
PEY10 |
OXIDATIVE STRESS IN ADVANCED PRIMARY OPEN-ANGLE GLAUCOMA |
|
Zanon-Moreno V1, Pons S1, Garcia-Medina JJ2, Gallego-Pinazo R3, Vinuesa-Silva I4, Marco-Ventura P1, Pinazo-Duran M4 |
|
1Universitary Hospital Dr. Peset, Valencia, Spain, 2Hospital La Inmaculada, Huercal Overa, Almeria, Spain, 3Hospital La Fe, Valencia, Spain, 4Hospital Punta de Europa, Algeciras, Cadiz, Spain |
| |
|
PEY11 |
ESTIMATING NET HEALTH BENEFITS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD) |
|
Levy AR1, Szabo SM1, Zlateva G2, Briggs A3, Pleil A4 |
|
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Pfizer Inc, New York, NY, USA, 3University of Glasgow, Glasgow, UK, 4Pfizer Inc, San Diego, CA, USA |
| |
|
PEY12 |
METHODOLOGICAL ISSUES ARISING FROM THREE STUDIES WHICH INCLUDED CONJOINT ANALYSIS IN VISUALLY IMPAIRED PEOPLE |
|
Aspinall PA1, Brice R2, Vickers A2, Steeds CS3, Buchholz P4 |
|
1Heriot-Watt University, Edinburgh, UK, 2Adelphi Group Ltd, Bollington, Cheshire, UK, 3CS Consulting, Motherwell, Scotland, UK, 4Allergan Europe, Ettlingen, Germany |
| |
|
PEY13 |
TIME TO DISCONTINUATION OF GLAUCOMA MEDICINES PRESCRIBED SUBSEQUENT TO INITIAL THERAPY |
|
Montgomery DMI1, Witchalls A1, Pleil A2 |
|
1Glasgow Royal Infirmary, Glasgow, UK, 2Pfizer Inc, San Diego, CA, USA |
| |
|
PEY14 |
ASSESSMENT OF THE PERSISTENCE DEGREE IN PATIENTS WITH ANTIGLAUCOMA AGENTS AS FIRST LINE MONOTHERAPIES IN SPAIN |
|
Arias A1, Schargel K2, Ussa F3, Canut MI4, Martí B5, Soto J6 |
|
1Hospital de Alcorcón, Alcorcón, Madrid, Spain, 2Hospital de Torrevieja, Torrevieja, Alicante, Spain, 3Instituto Universitario de Oftalmobiología Aplicada, Valladolid, Spain, 4Centro de Oftalmología Barraquer, Barcelona, Spain, 5Universidad Autónoma de Madrid, Madrid, Madrid, Spain, 6Pfizer Spain, Madrid, Spain |
| |
|
PEY15 |
HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS IN FRANCE |
|
Soubrane G1, Zlateva G2, Xu X3, Goss TF3, Buggage R2, Kosa M4 |
|
1Centre Hospitalier Intercommunal de Créteil, Créteil, France, 2Pfizer Inc, New York, NY, USA, 3Covance Market Access Services, Gaithersburg, MD, USA, 4Pfizer, Paris, France |
| |
|
PEY16 |
CULTURAL ADAPTATION AND PARTIAL VALIDATION OF THE GLAUCOMA SYMPTOM SCALE (GSS) TO SPANISH |
|
Ruiz MA1, Pardo A1, Martínez de la Casa JM2, Polo V3, Esquirol J4, Soto J5, Jiménez S6 |
|
1Universidad Autónoma de Madrid, Madrid, Spain, 2Fundación Hospital Alcorcón, Madrid, Spain, 3Hospital Universitario Miguel Servet, Zaragoza, Spain, 4Centro Médico Tecnón, Barcelona, Spain, 5Pfizer Spain, Madrid, Spain, 6Pfizer España, Madrid, Spain |
|
|
GI DISORDERS
PGI1 |
DETERMINATION OF MINIMAL IMPORTANT DIFFERENCES (MIDS) AND INTERPRETATION OF SF-36 SCORES IN PATIENTS SUFFERING FROM MODERATE-TO-SEVERE CROHN'S DISEASE |
|
Keininger D1, Feagan BG2, Coteur G3, Kosinski M4 |
|
1UCB S.A, Braine-l’Alleud, Belgium, 2Robarts Research Institute, London, Ontario, Canada, 3SGS Life Sciences, Mechelen, Belgium, 4QualityMetric Incorporated, Lincoln, RI, USA |
| |
|
PGI2 |
PROTON PUMP INHIBITORS FOR THE INITIAL TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GORD) SYMPTOMS IN PATIENTS WITH REFLUX OESOPHAGITIS: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS |
|
Edwards SJ, Borrill J |
|
AstraZeneca UK Ltd, Luton, UK |
| |
|
PGI3 |
BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE |
|
Trichard M, Largeron N, Soum S, Saint-Sardos C |
|
sanofi pasteur MSD, Lyon, France |
| |
|
PGI4 |
ECONOMIC EVALUATION COMPARING LANSOPRAZOLE AND ESOMEPRAZOLE IN THE ACUTE MANAGEMENT OF UNINVESTIGATED DYSPEPSIA |
|
Mason J1, Lloyd AC2, Holman AJ2, Jobanputra M3 |
|
1University of Durham, Queen's Campus, Stockton-on-Tees, Durham, UK, 2Fourth Hurdle Consulting, London, UK, 3Wyeth Pharmaceuticals, Maidenhead, Berkshire, UK |
| |
|
PGI5 |
EVALUATION OF THE COST-EFFECTIVENESS OF CONCOMITANT ORAL AND TOPICAL MESALAZINE TREATMENT VERSUS ORAL TREATMENT ALONE IN MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS: A DECISION-ANALYTIC MODEL |
|
Nielsen SK1, Connolly MP1, Bhatt A1, Currie CJ2 |
|
1Ferring International Center, Saint-Prex, Switzerland, 2Cardiff University, Cardiff, UK |
| |
|
PGI6 |
PHARMACOECONOMIC ANALYSIS OF PROTON PUMP INHIBITORS ON C & D ESOPHAGITIS TREATMENT IN SPAIN |
|
Cordero L1, Jimenez J1, Hernandez R2, Coll E1 |
|
1AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 2AstraZeneca, Madrid, Spain |
| |
|
PGI7 |
COST-EFFECTIVENESS ANALYSIS OF TREATING CHORNIC HEPATITITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN EARLY BEFORE DISEASE PROGRESSES TO MORE ADVANCED STAGE |
|
Ravasio R1, Giuliani G2 |
|
1Wolters Kluwer Health, Milano, Italy, 2Roche S.p.A, Milano, Italy |
| |
|
PGI8 |
COST-EFFECTIVENESS OF ESOMEPRAZOLE IN THE TREATMENT OF ADOLESCENT PATIENTS WITH REFLUX OESOPHAGITIS |
|
Borrill J, Edwards SJ |
|
Astrazeneca UK Ltd, Luton, UK |
| |
|
PGI9 |
PHARMACOECONOMIC ANALYSIS OF GERD TREATMENT AFTER OMEPRAZOLE FAILURE IN SPAIN |
|
Cordero L1, Jimenez J1, Hernandez R2, Coll E1 |
|
1AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 2AstraZeneca, Madrid, Spain |
|
|
PGI10 |
WITHDRAWN |
| |
|
PGI11 |
IMPACT OF CONSTIPATION ON HEALTH CARE UTILIZATION AND COSTS IN PATIENTS ON OPIOID THERAPY |
|
Candrilli SD1, Iyer S2, Davis KL1 |
|
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Wyeth Research, Collegeville, PA, USA |
| |
|
PGI12 |
THE DUEC (DIGITAL ULCERS ECONOMIC COST) STUDY: ECONOMIC BURDEN OF DIGITAL ULCERS IN ITALIAN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS |
|
Lopatriello S1, Tiso F2, Cozzi F2, Punzi L2, Berto P1 |
|
1pbe consulting, Verona, Italy, 2Azienda Ospedaliera di Padova, Padova, Italy |
| |
|
PGI13 |
THE EPIDEMIOLOGY AND HEALTHCARE RESOURCE USE IN PATIENTS WITH CROHN'S DISEASE: A POPULATION BASED UK STUDY |
|
Woehl A1, Hawthorne AB2, Morgan CL1, Punekar Y3, McEwan P4 |
|
1Cardiff University, Cardiff, UK, 2University Hospital of Wales, Cardiff, UK, 3Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK, 4Cardiff Research Consortium, Cardiff, UK |
| |
|
PGI14 |
THE EPIDEMIOLOGY AND HEALTHCARE RESOURCE USE IN PATIENTS WITH ULCERATIVE COLITIS: A POPULATION BASED UK STUDY |
|
Woehl A1, Hawthorne AB2, Morgan CL1, Punekar Y3, McEwan P4 |
|
1Cardiff University, Cardiff, UK, 2University Hospital of Wales, Cardiff, UK, 3Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK, 4Cardiff Research Consortium, Cardiff, UK |
| |
|
PGI15 |
PERSISTENCE WITH INFLIXIMAB THERAPY REDUCES CROHN'S DISEASE RELATED MEDICAL COSTS |
|
Thompson HC1, Rahman MI1, Meissner B2, Tang B1, Dabbous O1 |
|
1Centocor, Inc, Horsham, PA, USA, 2Xcenda, LLC, Palm Harbor, FL, USA |
| |
|
PGI16 |
AN EXPLORATORY ANALYSIS OF HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH PEDIATRIC CROHN'S DISEASE |
|
Thompson HC1, Teng E2, Rahman MI1, Ferrer R2, Tang B1, Dabbous O1, Pulicharam RJ3 |
|
1Centocor, Inc, Horsham, PA, USA, 2HealthCare Partners Corporate, Torrance, CA, USA, 3HealthCare Partners LA, Los Angeles, CA, USA |
| |
|
PGI17 |
INCRE | | |